Journal ArticleDOI
Anti-cancer drugs
Reads0
Chats0
About:
This article is published in Current Pharmaceutical Design.The article was published on 2005-03-31. It has received 882 citations till now. The article focuses on the topics: Introductory Journal Article.read more
Citations
More filters
Journal ArticleDOI
Antitumor Activity of β-Cyclodextrin Polymer−Camptothecin Conjugates
TL;DR: It is demonstrated that a short course of treatment with the polymer conjugates of CPT gives long-term control of tumor growth that does not occur with either CPT or irinotecan.
Journal ArticleDOI
Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study
Angela Casini,Gerhard Kelter,Chiara Gabbiani,Maria Agostina Cinellu,Giovanni Minghetti,Dolores Fregona,Heinz H. Fiebig,Luigi Messori +7 more
TL;DR: The results conclusively qualify gold(III) compounds as a promising class of cytotoxic agents, of outstanding interest for cancer treatment, while providing initial insight into their modes of action.
Journal ArticleDOI
Development of novel therapeutic strategies that target HIF-1
TL;DR: Several novel compounds with anticancer activity have been shown to inhibit HIF-1 and may be useful as components of individualised multidrug therapeutic regimens chosen based on molecular analyses of tumour biopsies.
Journal ArticleDOI
Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide.
TL;DR: The artemisinin-peptide conjugates showed potent anti-cancer activity against Molt-4 leukemia cells with a significantly improved cancer/normal cells selectivity.
Journal ArticleDOI
Hyperbranched Double Hydrophilic Block Copolymer Micelles of Poly(ethylene oxide) and Polyglycerol for pH-Responsive Drug Delivery
TL;DR: It is demonstrated the hyperbranched PEO-hb-PG can form a self-assembled micellar structure on conjugation with the hydrophobic anticancer agent doxorubicin, which is linked to the polymer by pH-sensitive hydrazone bonds, resulting in a pH-responsive controlled release of doxorbicin.
References
More filters
Journal ArticleDOI
The status of platinum anticancer drugs in the clinic and in clinical trials.
TL;DR: The status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials are updated, and the results in the context of where the field will develop over the next decade are discussed.
Journal ArticleDOI
Natural products to drugs: natural product derived compounds in clinical trials
Mark S. Butler,Mark S. Butler +1 more
TL;DR: Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural products for which clinical trials have been halted or discontinued since 2005.
Journal ArticleDOI
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
John Ramage,A Ahmed,J Ardill,N.D.S. Bax,David J. Breen,Martyn Caplin,Pippa Corrie,J Davar,Albert Davies,Val Lewington,Tim Meyer,John Newell-Price,Graeme J. Poston,N. Reed,Andrea Rockall,William P. Steward,Rajesh V. Thakker,C. Toubanakis,Juan W. Valle,Caroline S. Verbeke,Ashley B. Grossman +20 more
TL;DR: These guidelines update previous guidance published in 2005 and have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinical committees of the British Society of Gastroenterology and others.
Journal ArticleDOI
Cellular distribution and functions of P2 receptor subtypes in different systems.
TL;DR: This review is aimed at providing readers with a comprehensive reference article about the distribution and function of P2 receptors in all the organs, tissues, and cells in the body.
Journal ArticleDOI
Natural products: an evolving role in future drug discovery.
Bhuwan B. Mishra,Vinod K. Tiwari +1 more
TL;DR: The present review describes natural products, semi-synthetic NPs and NP-derived compounds that have undergone clinical evaluation or registration from 2005 to 2010 by disease area i.e. infectious, immunological, cardiovascular, neurological, inflammatory and related diseases and oncology.